Human Platelets and Derived Products in Treating Ocular Surface Diseases - A Systematic Review.

You, J; Hodge, C; Hoque, M; Petsoglou, C; Sutton, G

Human Platelets and Derived Products in Treating Ocular Surface Diseases - A Systematic Review.

You, J Hodge, C

Hoque, M Petsoglou, C Sutton, G

Permalink

Publisher:: Dove Medical Press
Publication Type:: Journal Article
Citation:: Clinical Ophthalmology, 2020, 14, pp. 3195-3210
Issue Date:: 2020-01

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (368.91 kB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	You, J
dc.contributor.author	Hodge, C https://orcid.org/0000-0002-0516-6486
dc.contributor.author	Hoque, M
dc.contributor.author	Petsoglou, C
dc.contributor.author	Sutton, G
dc.date.accessioned	2021-05-23T20:57:57Z
dc.date.available	2020-08-26
dc.date.available	2021-05-23T20:57:57Z
dc.date.issued	2020-01
dc.identifier.citation	Clinical Ophthalmology, 2020, 14, pp. 3195-3210
dc.identifier.issn	1177-5467
dc.identifier.issn	1177-5483
dc.identifier.uri	http://hdl.handle.net/10453/149083
dc.description.abstract	Human platelet products have emerged as an alternative treatment for a range of ocular surface diseases such as dry eye and corneal ulceration. With significant therapeutic potential and increasing popularity, this study aimed to conduct a systematic review to detail the various production methods involved in generating platelet-derived products, compare and analyze clinical findings across available studies, and disseminate the relative advantages, limitations, and challenges of using platelet products to treat ocular surface disease. Thirty-eight clinical studies were identified, excluding studies conducted in animals and non-English language. Studies reported clinical outcomes, which included ocular surface disease index, best-corrected visual acuity, and corneal fluorescein staining. Most clinical studies reported improved patient signs and symptoms with an increasing variety of human platelet products including platelet rich plasma eye drops, human platelet lysate and platelet gels. However, due to variations in production methods, and study designs as well as confusing terminology, it was suggested that characterization of platelet products is needed for proper evaluation across studies.
dc.format	Electronic-eCollection
dc.language	eng
dc.publisher	Dove Medical Press
dc.relation.ispartof	Clinical Ophthalmology
dc.relation.isbasedon	10.2147/opth.s265701
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	1113 Opthalmology and Optometry
dc.title	Human Platelets and Derived Products in Treating Ocular Surface Diseases - A Systematic Review.
dc.type	Journal Article
utslib.citation.volume	14
utslib.location.activity	New Zealand
utslib.for	1113 Opthalmology and Optometry
utslib.for	1113 Opthalmology and Optometry
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Orthoptics
utslib.copyright.status	open_access	*
pubs.consider-herdc	true
dc.date.updated	2021-05-23T20:57:55Z
pubs.publication-status	Published
pubs.volume	14

Abstract:

Human platelet products have emerged as an alternative treatment for a range of ocular surface diseases such as dry eye and corneal ulceration. With significant therapeutic potential and increasing popularity, this study aimed to conduct a systematic review to detail the various production methods involved in generating platelet-derived products, compare and analyze clinical findings across available studies, and disseminate the relative advantages, limitations, and challenges of using platelet products to treat ocular surface disease. Thirty-eight clinical studies were identified, excluding studies conducted in animals and non-English language. Studies reported clinical outcomes, which included ocular surface disease index, best-corrected visual acuity, and corneal fluorescein staining. Most clinical studies reported improved patient signs and symptoms with an increasing variety of human platelet products including platelet rich plasma eye drops, human platelet lysate and platelet gels. However, due to variations in production methods, and study designs as well as confusing terminology, it was suggested that characterization of platelet products is needed for proper evaluation across studies.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/149083